Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026
Mobia Medical (MOBI) will report its third quarter 2026 financial results on November 5, 2026, followed by a management call.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mobia Medical (MOBI) will report its third quarter 2026 financial results on November 5, 2026, followed by a management call. The conference call and webcast will begin at 4:30 p.m. ET to discuss the results and provide a corporate update. A live and archived webcast will be available through the News & Events page of the company’s investor website.
Key Figures
- Results reporting date
- November 5, 2026
- Third quarter 2026 financial results
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Company will report third quarter 2026 financial results on Thursday, November 5, 2026. Mobia Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast can also be accessed via the News & Events page of the investor section of Mobia Medical’s website.
About Mobia Medical, Inc.
Mobia Medical, Inc. is a medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.
Investor Relations Contact
Louisa Smith
Gilmartin Group, LLC
investors@mobia.com
